Health Condition 1: M628- Other specified disorders of muscle
Conditions
Interventions
Intervention1: DAN MR: DAN MR is the fixed dose combination of Paracetamol,Chlorzoxazone and Diclofenac sodium. Combination of these drugs provide anti- inflammatory as well as analgesic effect and wi
Sponsors
Unison Pharmaceuticals Pvt. Ltd.
Eligibility
Inclusion criteria
Inclusion criteria: 01. Patients who have given their written consent to participate voluntarily and agrees to adhere to the protocol for completion of study. 02.Male and Female between the age of 18 to 60. 03.Patient is able to take oral medication and is willing to comply with the treatment schedule as well as all study procedures. 04.Patient s willingness to comply with all study procedures and availability for the duration of the study. 05.Female participants must be non-lactating, not pregnant, and utilizing a reliable method of contraception, such as abstinence, an intrauterine device (IUD), or a male partner who agrees to use condoms. 06.Male participants must agree to use a reliable method of contraception, such as abstinence, condoms, or having a partner who utilizes an intrauterine device (IUD). 07.Patients diagnosed (by the treating physician/PI) to have Acute Painful musculospastic condition such as prolapsed intervertebral disc, sprains and dislocations, spondylosis (lumbar, cervical, ankylosing spondylosis), spinal stenosis, periarthritis, frozen shoulder, prepatellar bursitis, spondylolisthesis, low-backpain, tendonitis, tenosynovitis, bursitis, and as self-rated 7-10 on the Numerical pain scale.08.Patients must agree to abstain from consuming Alcohol, any other substance of abuse during their participation in the trial.
Exclusion criteria
Exclusion criteria: 01. Active participation in any other clinical trial. 02. Known allergy to the study drugs used in the trial. (Diclofenac, Paracetamol, Chlorzoxazone). 03. Patients with any other clinically significant uncontrolled systemic diseases such as gastrointestinal, respiratory, cardiovascular, renal, neurological, psychiatric, endocrine, immunological or hematological disorders or malignancy as judged by the investigator. 04.Patients taking any other medicine that might interact with one of the study medications. 05.History of auto-immune disease. 06.Active peptic ulcer disease. 07. Pregnant females, lactating women or women of childbearing age who are not using an acceptable method of birth control. 08. Patients with a history of epilepsy, or those at-risk seizures or taking antiepileptic drugs. 09. Patient with known G6PD deficiency. 10.Patients with pre-existing gallbladder disease. 11. Patients with galactose or fructose intolerance 12. Patients with active liver disease, including primary biliary cirrhosis and unexplained persistent liver function abnormalities. 13. Alcohol dependence or any other condition that may affect the study, as assessed by the Investigator. 14. Patients with concomitant use of other NSAIDs, antiplatelets, anticoagulants or any other aid for pain. 15. Patients needing any treatment (associated with muscle spasm) other than the study drugs - as diagnosed by the Investigator. 16. Any history/ symptoms/ suspicion of patients having hepatic or renal impairment, as judged by the Principal Investigator. 17. If patient is on any other treatment or additional treatment aid for pain (oral, dermal, drug-plaster, heat-pad or any similar contact therapy, herbal, homeopathic or any other nature) during the study duration. 18. Patients with any severe and/or uncontrolled medical conditions or other conditions that, in the investigator s opinion may affect the patient s participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of patients who shows any incidence of drug associated adverse effect during 8 days of treatment Percentage of patients where the PI needs to stop the treatment before day 8 due to drug-associated toxicityTimepoint: Percentage of patients who shows any incidence of drug associated adverse effect during 8 days of treatment Percentage of patients where the PI needs to stop the treatment before day 8 due to drug-associated toxicity | — |
Secondary
| Measure | Time frame |
|---|---|
| Percentage reduction in pain at day 8 Percentage of the patients where the PI stops the treatment before the day 8, as the pain has subsided & the need for pain management does not exist anymore.Timepoint: 8 Days | — |
Countries
India
Contacts
Public ContactBharat B Doshi
BioDev Services Private Limited
Outcome results
None listed